contravir.comHepion Pharmaceuticals
contravir.com Profile
contravir.com is a domain
that was created on 2013-05-16,making it 11 years ago.
It has several subdomains, such as ir.contravir.com , among others.
Discover contravir.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
contravir.com Information
| HomePage size: 105.977 KB |
| Page Load Time: 0.260892 Seconds |
| Website IP Address: 104.198.5.36 |
contravir.com Similar Website
| Aridis Pharmaceuticals - Welcome |
| Clinical Trials | Regeneron Pharmaceuticals |
| Investor Relations :: CNS Pharmaceuticals, Inc. (CNSP) |
| Mirum Pharmaceuticals, Inc. - Investor Relations |
| The Power of the Microbiome | Ferring Pharmaceuticals |
| Investor Relations - Supernus Pharmaceuticals |
| Amneal Pharmaceuticals, Inc. - Investor Relations |
| Investors :: Conatus Pharmaceuticals Inc. (CNAT) |
| Eagle Pharmaceuticals Investor Center | |
| Alcon Completes Acquisition of Aerie Pharmaceuticals | Alcon.com |
| Investor Relations - Spectrum Pharmaceuticals, Inc. |
| TopRx – Home – National Supplier of Generic Pharmaceuticals |
| Ligand Pharmaceuticals Incorporated - Investor Relations |
| Ironwood Pharmaceuticals, Inc. - Company Overview |
| Lifeline Pharmaceuticals, LLC’s Login Page | Lifeline Pharmaceuticals, LLC |
contravir.com PopUrls
| Non-alcoholic Steatohepatitis (NASH) https://contravir.com/nash/ |
| Rencofilstat Overview https://contravir.com/crv431/ |
| Publications https://contravir.com/publications/ |
| Hepion Pharmaceuticals https://www.contravir.com/ |
| Hepatocellular Carcinoma (HCC) https://contravir.com/hcc/ |
| Therapeutic Strategy https://contravir.com/strategy/ |
| About Hepion https://contravir.com/about/ |
| Leadership – Hepion Pharmaceuticals https://contravir.com/leadership/ |
| Workplace Development, Diversity, and Inclusion Statement https://contravir.com/wddi/ |
| Pipeline https://contravir.com/pipeline |
contravir.com DNS
| A contravir.com. 600 IN A 104.198.5.36 |
| MX contravir.com. 3600 IN MX 0 contravir-com.mail.protection.outlook.com. |
| NS contravir.com. 3600 IN NS ns01.domaincontrol.com. |
| TXT contravir.com. 3600 IN TXT v=spf1 include:spf.protection.outlook.com -all |
| SOA contravir.com. 3600 IN SOA ns01.domaincontrol.com. dns.jomax.net. 2019072302 28800 7200 604800 600 |
contravir.com Httpheader
| Date: Tue, 14 May 2024 06:21:55 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| Vary: Accept-Encoding, Accept-Encoding, Accept-Encoding, Accept-Encoding,Cookie |
| X-Pingback: https://hepionpharma.com/xmlrpc.php |
| Link: https://hepionpharma.com/wp-json/; rel="https://api.w.org/", https://hepionpharma.com/wp-json/wp/v2/pages/13; rel="alternate"; type="application/json", https://hepionpharma.com/; rel=shortlink |
| X-Powered-By: WP Engine |
| X-Cacheable: SHORT |
| Cache-Control: max-age=600, must-revalidate |
| X-Cache: HIT: 1 |
| X-Cache-Group: normal |
| CF-Cache-Status: DYNAMIC |
| Server: cloudflare |
| CF-RAY: 8838ca758b05ef53-PDX |
| alt-svc: h3=":443"; ma=86400 |
contravir.com Meta Info
| charset="utf-8"/ |
| content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport" |
| content="max-image-preview:large" name="robots"/ |
| content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress." name="generator"/ |
| content="https://hepionpharma.com/wp-content/uploads/2019/09/cropped-Hepion-Favicon-270x270.png" name="msapplication-TileImage"/ |
contravir.com Ip Information
| Ip Country: United States |
| City Name: The Dalles |
| Latitude: 45.6056 |
| Longitude: -121.1807 |
contravir.com Html To Plain Text
Hit enter to search or ESC to closeMenu About Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-alcoholic Steatohepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis AI-POWR™ Pipeline Overview Rencofilstat Therapeutic Strategy Clinical Trials Publications Expanded Access Policy Newsroom Investors Investor Overview Press Releases Events Presentations Company Information Stock Information SEC Filings Corporate Governance Contact Contact Us Careers twitter linkedin TACKLING CHRONIC LIVER DISEASE TACKLING CHRONIC LIVER DISEASE BROAD SPECTRUM LIVER THERAPY NASH, hepatitis, cirrhosis, liver failure, cancer. Half a billion people worldwide are at risk unless new therapies are found. Introducing AI-POWR™ AI-POWR™ combines Artificial Intelligence, Machine Learning, and Deep Learning to decode disease, develop targeted therapies, and to select patients that will respond to Hepion therapies. Learn morePlay Video Rencofilstat Mechanism of Action Play Video Rencofilstat Mechanism of Action About ( Nasdaq: HEPA ) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH”), fibrotic diseases, hepatocellular carcinoma (HCC”), and other chronic diseases. The Company’s lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. Company Overview Leadership Partnering Investors Recent News Stock Information Pipeline Rencofilstat AI-POWR™ Contact Us Careers News Alerts Recent News Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial April 19, 2024 Strengthens Board of Directors with Appointment of Michael Purcell March 6, 2024 Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds February 16, 2024 View Newsroom Get Important News and Updates by Email Subscribe twitter linkedin © 2023 | Disclaimer & Terms of Use | WDDIAbout Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-alcoholic Steatohepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis AI-POWR™ Pipeline Overview Rencofilstat Therapeutic Strategy Clinical Trials Publications Expanded Access Policy Newsroom Investors Investor Overview Press Releases Events Presentations Company Information Stock Information SEC Filings Corporate Governance Contact Contact Us Careers twitter...
contravir.com Whois
Domain Name: CONTRAVIR.COM Registry Domain ID: 1801616821_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-05-10T13:45:28Z Creation Date: 2013-05-16T02:46:43Z Registry Expiry Date: 2025-05-16T02:46:43Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS01.DOMAINCONTROL.COM Name Server: NS02.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T19:23:13Z <<<